Tregeutix Inc. ("Tregeutix") is a biotech company whose mission is to create a future where autoimmune diseases and allergies can be safely and effectively managed through the strategic use of beneficial microbiota * species to guide the immune system.
To achieve this goal, Tregeutix is developing a proprietary platform to discover beneficial microbes that can support antigen-specific regulatory T cells (Tregs **) using a combination of computational and experimental methods. By leveraging beneficial microbes, Tregeutix aims to restore the balance of the immune system and alleviate symptoms of autoimmune diseases and allergies, which are intrinsically antigen-specific pathologies.
*Microbiota is the collection of microorganisms that live in and on our bodies, such as bacteria, fungi, and viruses. The microbiota influences many aspects of health, including immune system. Some microbiota species can induce or support Tregs.**Tregs are a type of white blood cell crucial for maintaining immune tolerance and preventing unwanted inflammation. They can suppress the activity of other immune cells implicated in autoimmune diseases and allergies.
Company Details
- Employees
- 2
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- tregeutix.com
Tregeutix Inc. Questions
Tregeutix Inc.'s website is tregeutix.com
Tregeutix Inc.'s LinkedIn profile is https://www.linkedin.com/company/tregeutix-inc
Tregeutix Inc. has
2 employees.
View email and phone details for 2
employees at Tregeutix Inc..
Tregeutix Inc.'s industry is
Biotechnology Research
Tregeutix Inc.'s top competitors are
Clutch Labs,
Quick-Med Technologies,
Mergenet Medical, Inc.,
Acumed,
Vuessence,
Applied Genetics Laboratories, Inc.,
Argus Endoptics,
Neocis.
Tregeutix Inc.'s categories are Biotechnology Research
Tregeutix Inc.'s founding year is 2017
